Magnolia Medical Technologies makes a product that aims to reduce the rate of false positive diagnoses of sepsis.
Seattle-based Magnolia Medical Technologies has raised $13.8 million to continue developing a product that aims to provide accurate blood tests.
Magnolia makes the SteriPath blood-collection system, which is meant to decrease the number of false positives for sepsis, a complication of a bloodstream infection that is often treated with antibiotics and can be life-threatening.
Such false positives can mean that patients are given procedures and treatments they don’t need, exposing them to more risk, Magnolia said in a news release announcing the funding. More than 1 million people in the U.S. are misdiagnosed with sepsis each year, the company said.
Menlo Park, Calif.-based HealthQuest Capital led the funding round and announced managing partner Garheng Kong would join Magnolia’s board.
Most Read Business Stories
- Canada's answer to Tesla is a $15,500 electric three-wheeler
- Forget Marie Kondo: There's a better, high-tech method to tidying up
- Property taxes dropping in half of King County cities after years of big increases
- REI CEO Jerry Stritzke resigns, saying he failed to disclose a 'personal' relationship
- California utility PG&E shares rise as regulator calms investors VIEW
SteriPath is commercially available, and the company will use the investment to expand the product into hospitals.